Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908462 | 0.87 | CYP19A1 (0.46) | CYP19A1PGRARNR3C2 | |
| SCHEMBL6913702 | 0.87 | CYP19A1 (0.46) | CYP19A1PGRARNR3C2 | |
| SCHEMBL13804522 | 0.87 | CYP19A1 (0.46) | CYP19A1PGRARNR3C2 | |
| SCHEMBL4587495 | 0.82 | CYP19A1 (0.44) | CYP19A1PGRARNR3C2 | |
| SCHEMBL6841601 | 0.79 | AR (0.48) | CYP19A1PGRARNR3C2 | |
| SCHEMBL13400874 | 0.79 | AR (0.48) | CYP19A1PGRARNR3C2 | |
| SCHEMBL13809834 | 0.79 | AR (0.58) | CYP19A1PGRARNR3C2 | |
| SCHEMBL1656805 | 0.79 | AR (0.58) | CYP19A1PGRARNR3C2 | |
| SCHEMBL6297465 | 0.74 | AR (0.47) | PGRARNR3C2 | |
| SCHEMBL7536116 | 0.74 | AR (0.47) | PGRARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| EP-1212345-B1 | ORALLY ACTIVE 7-ALPHA-ALKYL ANDROGENS | AKZO NOBEL NV (NL) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | CYP19A1 11/4885PGR 151/4885AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.